GLP-1 Weight Loss by Starting Weight: Why % Beats Pounds

If you have started a GLP-1 and gone looking for what to expect, you have probably run into a confusing mix of numbers. One person lost 40 pounds, another lost 20, a headline says “15% weight loss.” Which number should you compare yourself to? The honest answer is: the percentage. Almost every GLP-1 trial reports results as a percent of starting body weight, and there is a good reason for that. This piece explains why percentage beats pounds, how the same percent turns into wildly different pounds depending on where you start, and what the trial averages were.

If you want to see what a given percentage would mean for your own starting weight, you can estimate your own numbers with our GLP-1 weight loss projector before reading on.

Why the trials measure percent, not pounds

The big GLP-1 obesity trials (STEP for semaglutide, SURMOUNT for tirzepatide) all use percent change in body weight as their primary outcome. This is deliberate. A trial enrolls people across a wide range of starting weights, and pounds lost scale with how much you weighed to begin with. If you reported the raw average pounds lost, that number would depend heavily on who happened to be enrolled. Percentage normalizes for that: it lets you compare a 180-pound person and a 300-pound person on the same footing.

There is also a clinical reason. The health benefits of weight loss (improvements in blood sugar, blood pressure, and cardiometabolic risk) track more closely with the proportion of body weight lost than with the absolute pounds. A 10% loss is a recognized clinical threshold whether you started at 200 or 300 pounds. That is why percentage is the language your clinician, and the research, speaks.

The GLP-1 trials report results as a percentage of body weight, and that percentage is fairly consistent whether you start heavier or lighter.

The same percent, very different pounds

A single percentage becomes a completely different pound figure depending on your starting weight. Percent is the constant; pounds are the variable. The table below shows what a few benchmark percentages look like across starting weights:

Starting weight	10% loss	15% loss	20% loss
180 lb	18 lb	27 lb	36 lb
220 lb	22 lb	33 lb	44 lb
260 lb	26 lb	39 lb	52 lb
300 lb	30 lb	45 lb	60 lb

Read across any row and the pounds climb; read down any column and they climb again. This is simple arithmetic (percent × starting weight), so the table itself needs no citation. But it explains almost every “why did they lose more than me?” question. Someone starting at 300 pounds who hits 15% loses 45 pounds. Someone starting at 200 who hits the same 15% loses 30 pounds. They responded identically to the drug. The scale just tells two different stories.

What the trials actually averaged

In the STEP 1 trial, participants started at a mean body weight of about 230 pounds. Over 68 weeks, the semaglutide group lost a mean of 14.9% of body weight versus 2.4% on placebo, which worked out to a mean total reduction of about 33.7 pounds versus 5.7 pounds. Notice that the memorable figure is the percent; the pounds follow from the group’s starting weight.

Tirzepatide’s SURMOUNT-1 trial reported by dose, and Lilly published both the percentages and their pound equivalents for that trial’s population:

Tirzepatide dose	Mean weight loss (%)	Mean weight loss (lb)
5 mg	16.0%	~35 lb
10 mg	21.4%	~49 lb
15 mg	22.5%	~52 lb
Placebo	2.4%	~5 lb

Those pound figures are specific to that trial’s average starting weight. Apply the same percentages to a lighter or heavier person and the pounds shift accordingly, which is the point.

Does a higher starting weight mean a bigger percentage?

This is the common assumption: that heavier people lose a larger percentage, not just more pounds. The trial evidence does not really support that. Post hoc analyses of the STEP 1 data found semaglutide produced clinically meaningful percent weight loss across baseline BMI categories: people who started with a lower BMI and those who started higher lost similar proportions of their body weight. Heavier participants lost more total pounds (bigger starting number), but the percentage was broadly comparable.

So the intuition is half right. A higher starting weight usually means more pounds on the scale at any given percentage. It does not reliably mean a bigger percentage. If anything, this is reassuring for people who start at a lower weight and worry the drug “won’t do as much” for them.

How to benchmark your own progress

The practical upshot is a single habit: convert to percent before you compare. Your percentage is (pounds lost ÷ starting weight) × 100. That is the number that maps onto the trials and onto anyone else’s result, regardless of their size. Judging yourself by raw pounds against someone with a very different starting weight will almost always mislead you, usually into thinking you are doing worse (or better) than you really are.

A few honest framings worth keeping in mind:

• The trial figures are averages, not promises. In STEP 1, roughly 86% of participants lost at least 5%, about 69% lost at least 10%, and about 50% lost at least 15%, a wide spread. Some people land above the average, some well below.
• Percent loss slows as you go. Weight loss is not linear; it decelerates over months as your body adapts. We cover why in our explainer on the GLP-1 weight loss plateau.
• Response varies for reasons beyond starting weight. Genetics, dose, adherence, diet, and activity all move the needle. Our piece on predicting who responds to GLP-1s walks through the factors that actually matter.

The takeaway

GLP-1 results are reported in percentages because percentages are comparable across starting weights and track the health benefits that matter. The same percent loss becomes very different pounds depending on where you began (15% is roughly 30 pounds at 200 and 45 pounds at 300), so raw pounds are a poor yardstick for comparing yourself to anyone else. Convert your own loss to a percentage, compare that to the trial averages, and remember those averages come with a wide spread around them.

To turn a target percentage into a pound figure for your own starting weight, run the numbers in our GLP-1 weight loss projector. This article is educational and not medical advice. Decisions about your dose, goals, and progress belong with the clinician who knows your history.

Sources

• STEP 1 semaglutide trial summary (American College of Cardiology)
• STEP 1 summary — baseline weight and absolute loss (ACG EBGI)
• STEP 1 responder rates (WikiJournalClub)
• SURMOUNT-1 tirzepatide results by dose (Eli Lilly / PR Newswire)
• McGowan et al., “Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial,” Obesity (2023) — for consistency of percent loss across baseline BMI classes.